Related Experiment Video
Updated: Oct 29, 2025
08:12
Micro-dissection of Enamel Organ from Mandibular Incisor of Rats Exposed to Environmental Toxicants
Published on: March 29, 2018
10.3K
Tigecycline-Induced Tooth Discoloration in Children Younger than Eight Years
Zhengyi Zhu1, Qi Yu2, Ganggang Qi2
1Department of Pharmacy, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.
Antimicrobial Agents and Chemotherapy
|July 6, 2021
Summary
Tigecycline, a tetracycline derivative, may cause tooth discoloration in children under 8. Two of 12 pediatric patients showed yellow discoloration, but more research is needed to confirm this adverse event.
Area of Science:
- Pediatric Dentistry
- Pharmacology
- Dental Adverse Events
Background:
- Tetracycline antibiotics are known to cause tooth discoloration in young children.
- The potential for tooth discoloration from tigecycline, a tetracycline derivative, is not well-established.
Purpose of the Study:
- To assess the risk of permanent tooth discoloration in pediatric patients exposed to tigecycline.
- To investigate potential tetracycline-like adverse dental events associated with tigecycline use.
Main Methods:
- Retrospective chart review of patients under 8 years old exposed to tigecycline.
- Dental examination, photography, and assessment for discoloration by two independent dentists.
- Inclusion criteria required at least one erupted permanent tooth post-exposure.
Main Results:
- 101 patients exposed to tigecycline were identified; 12 were included in the final analysis.
- Two patients (16.7%) exhibited yellow tooth discoloration and opacities.
- Discoloration varied, including yellowing of incisors and suspicious buccal yellowing in molars.
Conclusions:
- Tigecycline exposure in young children may be associated with tooth discoloration.
- The small sample size and limited follow-up prevent definitive conclusions on incidence and extent.
- Further research with larger cohorts and longer follow-up is warranted to clarify tigecycline's dental safety profile.
Related Concept Videos
01:26Tonsillitis II: Management
225
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
225
01:15Teeth
1.0K
The formation of teeth, also known as odontogenesis, is a complex process that begins in utero, around the sixth week of embryonic development. There are three stages to this process: the bud stage, the cap stage, and the bell stage.
In the bud stage, the tooth germ (an aggregation of cells) starts to form in the developing jawbone. During the cap stage, the tooth germ differentiates into enamel organ, dental papilla, and dental sac, which will later develop into the tooth's enamel, dentin...
In the bud stage, the tooth germ (an aggregation of cells) starts to form in the developing jawbone. During the cap stage, the tooth germ differentiates into enamel organ, dental papilla, and dental sac, which will later develop into the tooth's enamel, dentin...
1.0K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
50
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
50
01:29Drug Dosing: Infants and Children
59
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
59
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
45
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
45
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
47
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
47